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Introduction
This report covers the period December 15, 2005 -December 14, 2006. Tuberous sclerosis is caused by mutations in the Tsc1 or Tsc2 gene. Products of these genes form a complex that acts as a negative regulator of Rheb GTPase. Rheb is an activator of mTOR. Thus, one of the major problems with tuberous sclerosis is that the Tsc/Rheb/mTOR signaling pathway is over-activated. Our research is focused on understanding how this signaling pathway is regulated and what the consequences of alteration of this signaling pathway are. We have made progress in experiments outlined in the Statement of Work. In addition to characterizing Rheb2, we have characterized altered cell cycle progression in the Tsc-null MEFs. We have generated novel mTOR mutants, important reagents to over-activate the Tsc/Rheb/mTOR signaling.
Summary of progress
Tuberous sclerosis is caused by the loss of Tsc1/Tsc2 complex that acts as a negative regulator of Rheb GTPase (Aspuria and Tamanoi, 2004) . This results in overactivation of the Rheb/mTOR signaling pathway. Our overall aim is to understand the consequences of altering this signaling pathway. During the current funding period, we have made progress in this pursuit by carrying out the following experiments. (i)We have further characterized Rheb2 protein.
(ii) We have elucidated how the overactivation of the Tsc/Rheb/mTOR signaling results in altered cell cycle progression. (iii) We have generated constitutive active mutant forms of mTOR that can bypass amino acid requirement for their activation. Effects of the expression of these mutants have been investigated.
Detailed description of accomplishments

To generate Rheb1 and Rheb2 knockout mice
We continued our effort to generate knockout mice. To accomplish this, we consulted with Dr. Michele Musacchio at the University of California Irvine. The targeting constructs for Rheb1 and Rheb2 were electroporated into mouse ES cells and the cells with correct chromosomal replacement were screened by Southern hybridization. After extensive screening of ES cells, we failed to identify knockout ES cells for either Rheb1 or Rheb2.
To characterize Rheb2
Previously, we have been successful in raising a polyclonal antibody against Rheb2 (RhebL1). This antibody detects mouse Rheb2 but not mouse Rheb1. It does not recognize human Rheb2. We have continued to characterize Rheb2 using this antibody. Mouse tissue samples (brain, heart, kidney, liver, testis and muscle) were used to examine tissue expression of Rheb2. Our results (Figure 1) show that Rheb2 is highly expressed in the brain. While Rheb1 is expressed ubiquitously, Rheb2 appears to exhibit tissue specific expression. Non-ubiquitous expression of human Rheb2 was recently reported (Yuan et al., 2005; Saito et al., 2005) .
3. To investigate the mechanism of regulation of cell cycle progression by the TSC/Rheb/mTOR signaling pathway
The loss of TSC leads to the activation of Rheb/ mTOR signaling resulting in altered cell growth. We have previously reported using Drosophila tissue culture cells that the TSC/Rheb/mTOR signaling pathway plays critical roles in cell cycle progression; inhibition of this signaling leads to cell cycle arrest at the G1 phase (Patel et al., 2003) . In the course of this grant, we found that the loss of TSC leads to altered cell growth in mammalian cells. This was shown using MEFs derived from Tsc-null mice. These cells do not respond to serum starvation and continue growing even in the absence of serum. Furthermore, they are not cell cycle inhibited after reaching high density. Cell cycle progression from G1 to S is regulated by the activity of Cdk2. We examined Cdk2 activity by immunoprecipitating Cdk2 and assaying kinase activity by using histone H1 as a substrate. This study showed that Cdk2 activity remains active even after serum starvation in the Tsc2-null MEFs ( Figure 2A ). Similarly, Cdk2 activity remains high after the Tsc2-null MEF cells reached high confluency ( Figure 2B ). In contrast, the level of Cdk2 is low in the control parental MEFs after serum starvation.
To gain insight into which cell cycle protein is affected by the alteration of the TSC/Rheb/mTOR signaling, we examined key proteins involved in cell cycle regulation such as cyclins and Cdk inhibitors. One of the consistently observed differences between the Tsc2-null MEF and control MEF concerns nuclear localization of p27. While nuclear translocation of p27 is observed after serum starvation in the control MEF, p27 was not detected in the nuclear fraction in the Tsc2-null MEF (Figure 3 ). In collaboration with Dr. Cheryl Walker (MD Anderson Cancer Center), it was shown that the nuclear translocation of p27 is dependent on its phosphorylation by AMPK. The AMPK phosphorylation sites on p27 have been identified. the other in the kinase domain. Most of the mutations we identified occur on residues that are conserved in mTOR.
In the study supported by this grant, we have introduced representative mutations into mTOR. A representative mutation from each domain, the FAT domain and the kinase domain, was selected. These mutant mTOR proteins were expressed in HEK293 cells and their effects on amino acid dependent growth were examined. As shown in Figures 4 and 5 , mTOR activity is dependent on the presence of amino acids. Therefore, mTOR activity is low when cells are amino acid starved. This is seen in Figure 4 that investigated mTOR activity after nutrient starvation by examining phosphorylation of S6 (A) or carrying out kinase activity of mTOR immuneprecipitates (B). While transfection of the wild type mTOR did not rescue nutrient starvation, significant level of mTOR activity was detected when constitutive active mTOR mutants were transfected. Therefore, these mutants confer amino acid independent growth.
Two types of mTOR complexes are present in mammalian cells. A complex termed mTORC1 contains mTOR, Raptor and mLST8 and is involved in growth control mediated by the stimulation of protein synthesis. Another complex mTORC2 contains mTOR, Rictor and mLST8 and is responsible for the phosphorylation of Akt. We examined whether our mutations also affect mTORC2 activity. The results obtained suggest that mTORC2 is unaffected by the activating mutations.
One possible mechanism for mTOR activation by the activating mutations is that the binding of mTOR associated proteins will be altered. To examine this point, mTOR was immunoprecipitated and the presence of associated proteins, Raptor, Rictor and mLST8 was examined. We find comparable levels of associated proteins with the constitutively active mTOR compared with the wild type protein ( Figure 6 ). Thus, the mutations do not affect overall structure of the mTOR complex.
Another important finding we made is that these mutations exert dominant effects. It is known that mTOR exists as a dimer. This was demonstrated by using two different mTOR tagged with different tags, AU1 and FLAG ( Figure 7 ). These mTOR are co-expressed. When AU1 mTOR was immunoprecipitated, we found that FLAG-mTOR also came down in the immuneprecipitates, suggesting that a dimer form of mTOR is present.
We then constructed AU1 tagged mutant mTOR and co-expressed it with FLAG tagged wild type mTOR. When FLAG-tagged mTOR was immunoprecipitated, we observed coprecipitation of AU1-mTOR. When the activity of this complex was examined, we found that it was active even in the presence of mutant mTOR. These results shown in Figure 7 provide evidence that the effects of mutations in mTOR can be dominant. This observation is important, as homozygous mutations could result in constitutive activation of mTOR. It will be interesting to actually identify mTOR mutations in tumor samples. Experiments are ongoing to test this possibility.
Another important observation we made concerns rapamycin that is evaluated in clinics as anticancer drugs. As shown in Figure 8 , rapamycin inhibited constitutively activated mTOR. In this experiment, the wild type and two different mutants of mTOR were transfected into cells. The cells were starved and then treated with rapamycin. Phosphorylation level of S6 was examined to assess the activity of mTOR. The results suggest that the activity of the mutant mTOR can still be inhibited by rapamycin.
Currently ongoing projects and plans for the next funding period
We plan to continue our approach to (i) characterize Rheb2, (ii) investigate the mechanism of cell cycle progression by the TSC/Rheb/mTOR signaling, (iii) elucidate mechanism of activation of mTOR and (iv) examine consequences of activation of mTOR. One particular emphasis is to identify mTOR mutations in tumor samples. Another emphasis is to generate cell lines stably expressing constitutive active mTOR mutants. HEK293 cells were transfected with a construct to express mTOR active mutants. Transfectants were selected by G418 and single clones were isolated. Stable expression of the mutant mTOR was confirmed. We plan to carry out a systematic analysis of the cells stably expressing mutant mTOR. One of the interesting questions is to examine whether growth properties such as the ability to grow on soft agar and the ability to respond to starvation are altered. In addition, morphology of the stable cell lines will be examined. Preliminary data suggest that these clones rescue the decrease in cell size by nutrient starvation. Further experiments will elucidate the mechanism by which mTOR regulates cell morphology. 
